Sign In
Buy TSHA
$5.86
-0.0150 (-0.255%)
At Close: Jul 31, 2026
Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16
07:00am, Wednesday, 11'th May 2022
DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene ther
Taysha Gene Therapies (TSHA) CEO RA Session II on Q4 2021 Results - Earnings Call Transcript
02:24pm, Thursday, 31'st Mar 2022
Taysha Gene Therapies (TSHA) CEO RA Session II on Q4 2021 Results - Earnings Call Transcript
Taysha Gene Therapies Gets A 'Thumbs Up'
01:50pm, Monday, 07'th Mar 2022
Shares of biopharmaceutical concern Taysha Gene Therapies, Inc. (TSHA) have lost over 70% of their value from their $20 IPO priced in September 2020.
BMEZ: Buy Low, Hold For The Distribution And Rebound
06:21am, Monday, 07'th Feb 2022
BMEZ: Buy Low, Hold For The Distribution And Rebound
Taysha Gene Therapies (TSHA) Stock: Why The Price Jumped Up Today
07:53am, Monday, 31'st Jan 2022
The stock price of Taysha Gene Therapies Inc (NASDAQ: TSHA) increased by over 18% pre-market today. This is why it happened.
Taysha Gene Therapies Stock (TSHA): Why The Price Increased Today
03:21pm, Thursday, 09'th Dec 2021
The stock price of Taysha Gene Therapies Inc (NASDAQ: TSHA) increased by over 7% during intraday trading today. This is why it happened.
TSHA Stock: Why It Increased Today
02:18pm, Tuesday, 05'th Oct 2021
The stock price of Taysha Gene Therapies Inc (NASDAQ: TSHA) increased by over 3% during intraday trading today. This is why it happened.
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences
04:00pm, Tuesday, 28'th Sep 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome
07:00am, Wednesday, 22'nd Sep 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome
04:00pm, Wednesday, 08'th Sep 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
Taysha Gene Therapies, Inc. (TSHA) CEO RA Session II on Q2 2021 Results - Earnings Call Transcript
03:06pm, Monday, 16'th Aug 2021
Taysha Gene Therapies, Inc. (TSHA) CEO RA Session II on Q2 2021 Results - Earnings Call Transcript
Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development
03:04pm, Monday, 16'th Aug 2021
Taysha Gene Therapies Inc (NASDAQ: TSHA) has entered into a loan and security agreement with Silicon Valley Bank (SVB), providing up to $100 million of borrowing capacity. $40 million is availabl
Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
07:03am, Monday, 16'th Aug 2021
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the tr
